| Rotigotine transdermal system shows dose-proportional pharmacokinetics and provides stable plasma concentrations over the 24-h application time period. |
| No relevant drug–drug interactions could be shown with typical concomitant medications or drugs with potential influence on the metabolism of rotigotine. |
| No influence of intrinsic factors like hepatic or renal impairment, age, or gender could be shown. |
| The behavior of rotigotine in the body is unaffected by Parkinson’s disease and restless legs syndrome disease states. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.